246
- Taylor WJ, Redden D, Dalbeth N, Schumacher HR, Edwards NL, Simon LS, et al. Application
of the OMERACT fi lter to measures of core outcome domains in recent clinical studies of
acute gout. J Rheumatol. 2014;41(3):574–80. - Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, et al. OMERACT endorse-
ment of measures of outcome for studies of acute gout. J Rheumatol. 2014;41(3):569–73. - Schumacher Jr HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome
measures for acute and chronic gout. J Rheumatol. 2005;32(12):2452–5. - Diaz-Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ. Concerns of patients with gout
are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout
studies. J Clin Rheumatol. 2014;20(3):138–40. - Taylor WJ. Gout measures: gout assessment questionnaire (gaq, gaq2.0), and physical mea-
surement of tophi. Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S59–63. - Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout assessment
questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract.
2006;60(10):1210–7. - Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results
in clinically important improvements in the health-related quality of life: short form-36 is
responsive to change in chronic gout. Rheumatology. 2011;50(4):740–5. - Ten Klooster PM, Oude Voshaar MA, Taal E, van de Laar MA. Comparison of measures of
functional disability in patients with gout. Rheumatology. 2011;50(4):709–13. - Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of
chronic gout. Qual Life Res. 2008;17(5):815–22. - Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease
strongly predicts hand function in patients with gout. Rheumatology. 2007;46(12):1804–7. - Lanser P, Gesell S. Pain management: the fi fth vital sign. Healthc Benchmarks. 2001;8(6):68–
70. 62. - Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe:
prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333. - Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol
and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike
arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–7. - Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice ther-
apy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331–4. - Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab
for acute gouty arthritis in patients with limited treatment options: results from two ran-
domised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann
Rheum Dis. 2012;71(11):1839–48. - Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Effi cacy of anakinra in gouty
arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. - Shrestha M, Chiu MJ, Martin RL, Cush JJ, Wainscott MS. Treatment of acute gouty arthritis
with intramuscular ketorolac tromethamine. Am J Emerg Med. 1994;12(4):454–5. - Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The
interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-
controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum
Dis. 2009;68(10):1613–7. - Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for
acute gout. Cochrane Database Syst Rev. 2013;4, CD009920. - Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of
acute pain. Acad Emerg Med Off J Soc Acad Emerg Med. 2001;8(12):1153–7. - Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for
acute gout. Cochrane Database Syst Rev. 2014;9, CD009993. - Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N. The health assessment
questionnaire disability index is a valid measure of physical function in gout. Clin Exp
Rheumatol. 2008;26(4):620–6.
J. Singh and N. Shah